Sigma Pharmaceuticals Ltd
.PNG)
SIP Details
· Negative sentiments posing pressure: Sigma Pharmaceuticals Ltd (ASX: SIP) stock fell over 6.04% on November 21, 2016 due to decline in market sentiments and impact from few analysts’ downgrade. On the other hand, SIP reported an Underlying EBIT rise of 17.0% in the first half of 2017. The group has a low net debt of $55.3 million. SIP is even enhancing Cash Conversion Cycle (CCC) by 8 to 10 days by Jan 2017.
· Recommendation: The shares of SIP fell over 8% in the last four weeks (as of November 18, 2016) due to concerns regarding government funding cuts. The stock is also trading at a relatively higher P/E. We give an “Expensive” recommendation at the current price of - $ 1.24
First half of 2017 performance (Source: Company Reports)
BT Investment Management Ltd
.PNG)
BTT Details
· Solid performance but volatility prevails: BT Investment Management Ltd (ASX: BTT) stock corrected over 6.2% on November 21, 2016 with continued volatility in financial sector, after rising over 20.48% in the last four weeks (as at November 18, 2016). The group reported a total revenue and other income rise of about 13% yoy to $500.06 million and a Net profit after income tax increase of 12% yoy to $142.02 million during the period. Cash NPAT reached $156 million from $132.46 million in 2015 which is an increase of 18% on the prior year. BTT declared a final dividend of 24.0 cents per share.
· Recommendation: BTT has been on uptrend since the last three months and generated over 23.8% returns. The rally has placed the stock at higher levels which is now trading at a high P/E. We give an “Expensive” recommendation at the current price of - $ 10.87
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in: BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or